Trinomab(Zhuhai)

Zhuhai, China · Founded 2015 · In IPO Registration

Developer of antibody biopharmaceuticals designed for related medical research services. Trinomab(Zhuhai) is based in Zhuhai, China and was founded in 2015. Its last reported valuation was $534 million in Jun 2025. It has raised $221 million.

Last reported valuation
$533.7M
Oct 2026
Priced at
—
Total raised
$221.2M
Last round
—

Who backs Trinomab(Zhuhai)?

27 investors
InvestorType
GL VenturesVenture capital
CICC CapitalPE / buyout
Shenzhen Guozhong Venture Capital ManagementVenture capital
Guolian InvestmentOther
Shenzhen Yifeng Investment Management EnterpriseVenture capital
Zhuhai Gree Financial InvestmentOther
Shenyin & Wanguo InvestmentVenture capital
Bank of China Group InvestmentPE / buyout
Superstring Capital ManagementHedge fund
Shangxin CapitalOther
+ 17 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Trinomab(Zhuhai) investors

27 investors are on record for Trinomab(Zhuhai), including GL Ventures, CICC Capital, Shenzhen Guozhong Venture Capital Management and Guolian Investment. By type, the record holds 4 venture capital firms and 2 private equity firms.

Free account
More of Trinomab(Zhuhai) with a free account
  • ·The complete investor list: 27 names
  • ·Watch Trinomab(Zhuhai): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 27 firms already write checks for companies like Trinomab(Zhuhai). Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View